CN110603258A - 抑制g12c突变型ras蛋白的杂芳基化合物 - Google Patents

抑制g12c突变型ras蛋白的杂芳基化合物 Download PDF

Info

Publication number
CN110603258A
CN110603258A CN201880030263.3A CN201880030263A CN110603258A CN 110603258 A CN110603258 A CN 110603258A CN 201880030263 A CN201880030263 A CN 201880030263A CN 110603258 A CN110603258 A CN 110603258A
Authority
CN
China
Prior art keywords
alkyl
halogen
heteroaryl
alkoxy
hydroxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880030263.3A
Other languages
English (en)
Chinese (zh)
Inventor
J.G.克特尔
S.K.巴加尔
S.博伊德
A.J.伊瑟顿
S.M.菲勒里
G.R.罗布
P.A.劳波
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN110603258A publication Critical patent/CN110603258A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201880030263.3A 2017-05-11 2018-05-08 抑制g12c突变型ras蛋白的杂芳基化合物 Pending CN110603258A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762504638P 2017-05-11 2017-05-11
US62/504638 2017-05-11
PCT/EP2018/061787 WO2018206539A1 (en) 2017-05-11 2018-05-08 Heteroaryl compounds that inhibit g12c mutant ras proteins

Publications (1)

Publication Number Publication Date
CN110603258A true CN110603258A (zh) 2019-12-20

Family

ID=62492577

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880030263.3A Pending CN110603258A (zh) 2017-05-11 2018-05-08 抑制g12c突变型ras蛋白的杂芳基化合物

Country Status (8)

Country Link
US (2) US20200109153A1 (enExample)
EP (1) EP3621968A1 (enExample)
JP (1) JP2020519589A (enExample)
CN (1) CN110603258A (enExample)
AR (1) AR111776A1 (enExample)
CA (1) CA3061650A1 (enExample)
TW (1) TW201906848A (enExample)
WO (1) WO2018206539A1 (enExample)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112390818A (zh) * 2019-08-12 2021-02-23 劲方医药科技(上海)有限公司 取代的杂芳环并二氢嘧啶酮衍生物，其制法与医药上的用途
WO2021239058A1 (zh) * 2020-05-27 2021-12-02 劲方医药科技(上海)有限公司 稠合三环类化合物、其药物组合物及用途
CN114075219A (zh) * 2020-08-14 2022-02-22 江苏恒瑞医药股份有限公司 喹啉稠环类衍生物、其制备方法及其在医药上的应用
WO2022135610A1 (zh) * 2020-12-25 2022-06-30 武汉誉祥医药科技有限公司 四并环化合物及其药物组合物和应用
WO2022188729A1 (en) * 2021-03-07 2022-09-15 Jacobio Pharmaceuticals Co., Ltd. Fused ring derivatives useful as kras g12d inhibitors
WO2022194245A1 (zh) * 2021-03-17 2022-09-22 劲方医药科技(上海)有限公司 嘧啶并环类化合物及其制法和用途
WO2022199587A1 (zh) * 2021-03-24 2022-09-29 南京明德新药研发有限公司 嘧啶并杂环类化合物及其应用
WO2022206723A1 (zh) * 2021-03-30 2022-10-06 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
WO2022268051A1 (zh) * 2021-06-21 2022-12-29 江苏恒瑞医药股份有限公司 稠合四环类化合物、其制备方法及其在医药上的应用
WO2023274383A1 (zh) * 2021-07-02 2023-01-05 上海迪诺医药科技有限公司 Kras g12d抑制剂及其应用
WO2023001141A1 (en) * 2021-07-23 2023-01-26 Shanghai Zion Pharma Co. Limited Kras g12d inhibitors and uses thereof
WO2023001123A1 (zh) * 2021-07-19 2023-01-26 上海艾力斯医药科技股份有限公司 新型吡啶并嘧啶衍生物
WO2023030385A1 (zh) * 2021-08-31 2023-03-09 劲方医药科技(上海)有限公司 嘧啶并环类化合物及其制法和用途
WO2023066371A1 (zh) * 2021-10-22 2023-04-27 江苏恒瑞医药股份有限公司 含氮的四环化合物、其制备方法及其在医药上的应用
WO2023072297A1 (zh) * 2021-11-01 2023-05-04 江苏恒瑞医药股份有限公司 含氮的四环化合物、其制备方法及其在医药上的应用
CN116867792A (zh) * 2021-02-09 2023-10-10 基因泰克公司 四环氧氮杂䓬化合物及其用途
WO2024022507A1 (zh) * 2022-07-29 2024-02-01 江苏恒瑞医药股份有限公司 一种包含kras g12d抑制剂的药物组合物
WO2024032702A1 (en) * 2022-08-11 2024-02-15 Beigene, Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2024032704A1 (en) * 2022-08-11 2024-02-15 Beigene, Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2024051721A1 (en) * 2022-09-07 2024-03-14 Nikang Therapeutics, Inc. Tetracyclic derivatives as kras inhibitors
WO2024120419A1 (en) * 2022-12-06 2024-06-13 Zai Lab (Shanghai) Co., Ltd. Fused tetracyclic compounds as kras g12d modulators and uses thereof
WO2024138486A1 (en) * 2022-12-29 2024-07-04 Nikang Therapeutics, Inc. Tetracyclic derivatives as kras inhibitors
WO2024197503A1 (en) * 2023-03-27 2024-10-03 Nikang Therapeutics , Inc. Tricyclic derivatives as kras inhibitors
WO2024217545A1 (zh) * 2023-04-21 2024-10-24 江苏恒瑞医药股份有限公司 一种含氮四环化合物的结晶形式及其制备方法
WO2024230734A1 (en) * 2023-05-08 2024-11-14 Jacobio Pharmaceuticals Co., Ltd. K-ras inhibitors and use thereof

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2969284T3 (es) 2018-01-19 2024-05-17 Medshine Discovery Inc Derivado de piridona-pirimidina que actúa como inhibidor de la muteína krasg12c
TW202012415A (zh) * 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物
WO2020085493A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 新規なインダゾール化合物又はその塩
EP3924053A1 (en) 2019-02-12 2021-12-22 Novartis AG Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
SG11202109451TA (en) * 2019-03-05 2021-09-29 Astrazeneca Ab Fused tricyclic compounds useful as anticancer agents
WO2020221239A1 (zh) * 2019-04-28 2020-11-05 劲方医药科技(上海)有限公司 氧杂氮杂喹唑啉-7(8h)-酮类化合物，其制法与医药上的用途
US12421236B2 (en) 2019-06-25 2025-09-23 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor
WO2021000885A1 (zh) * 2019-07-01 2021-01-07 江苏恒瑞医药股份有限公司 喹唑啉酮类衍生物、其制备方法及其在医药上的应用
CA3149403A1 (en) * 2019-08-02 2021-02-11 Shanghai Jemincare Pharmaceuticals Co., Ltd Tetracyclic compound, preparation method and use thereof
TWI761961B (zh) * 2019-09-20 2022-04-21 大陸商上海濟煜醫藥科技有限公司 稠合吡啶酮類化合物及其製備方法和應用
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
CN114929706A (zh) * 2019-09-29 2022-08-19 百济神州有限公司 Kras g12c的抑制剂
CN112574224A (zh) * 2019-09-30 2021-03-30 上海迪诺医药科技有限公司 Kras g12c抑制剂及其应用
PE20221253A1 (es) 2019-10-28 2022-08-16 Merck Sharp & Dohme Inhibidores de pequenas moleculas de mutante g12c de kras
CN112745335B (zh) * 2019-10-30 2024-08-30 武汉誉祥医药科技有限公司 一种三并杂环化合物及其用途
JP2023501208A (ja) 2019-11-01 2023-01-18 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺有害生物的に活性な縮合二環式芳香族複素環式化合物
BR112022008535A2 (pt) 2019-11-04 2022-08-09 Revolution Medicines Inc Composto, composição farmacêutica, métodos para tratar câncer e um distúrbio relativo à proteína ras
CR20220241A (es) 2019-11-04 2022-08-03 Revolution Medicines Inc Inhibidores de ras
US11739074B2 (en) 2019-11-04 2023-08-29 Revolution Medicines, Inc. Ras inhibitors
CN114980976A (zh) * 2019-11-27 2022-08-30 锐新医药公司 共价ras抑制剂及其用途
US12479834B2 (en) 2019-11-29 2025-11-25 Taiho Pharmaceutical Co., Ltd. Phenol compound or salt thereof
NZ788613A (en) * 2019-12-11 2025-07-25 Lilly Co Eli Kras g12c inhibitors
CN111039845A (zh) * 2019-12-18 2020-04-21 大连奇凯医药科技有限公司 一种4-氟-7-溴靛红的制备方法
CN114761408B (zh) * 2019-12-19 2023-09-15 贝达药业股份有限公司 Kras g12c抑制剂及其在医药上的应用
GB202001344D0 (en) 2020-01-31 2020-03-18 Redx Pharma Plc Ras Inhibitors
WO2023205701A1 (en) 2022-04-20 2023-10-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
KR20220164015A (ko) * 2020-04-03 2022-12-12 메드샤인 디스커버리 아이엔씨. 옥타하이드로피라지노디아자나프티리딘 디온 화합물
TW202210633A (zh) 2020-06-05 2022-03-16 法商昂席歐公司 用於治療癌症之dbait分子與kras抑制劑的組合
EP4168002A1 (en) 2020-06-18 2023-04-26 Revolution Medicines, Inc. Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
CN113980032B (zh) * 2020-07-27 2023-06-16 江苏恒瑞医药股份有限公司 稠合四环类衍生物、其制备方法及其在医药上的应用
IL301062A (en) 2020-09-03 2023-05-01 Revolution Medicines Inc Use of sos1 inhibitors to treat malignancies with shp2 mutations
US11690915B2 (en) 2020-09-15 2023-07-04 Revolution Medicines, Inc. Ras inhibitors
MX2023003338A (es) 2020-09-23 2023-06-14 Erasca Inc Piridonas y pirimidonas tricíclicas.
TWI880049B (zh) 2020-12-04 2025-04-11 美商美國禮來大藥廠 Kras g12c抑制劑
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
AU2022254674A1 (en) * 2021-04-08 2023-10-12 Genentech, Inc. Oxazepine compounds and uses thereof in the treatment of cancer
EP4334325A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
IL308193A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors
US20240293558A1 (en) 2021-06-16 2024-09-05 Erasca, Inc. Kras inhibitor conjugates
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
WO2022268648A1 (en) 2021-06-24 2022-12-29 Syngenta Crop Protection Ag 2-[3-[1 [(quinazolin-4-yl)amino]ethyl]pyrazin-2-yl]thiazole-5-carbonitrile derivatives and similar compounds as pesticides
TW202327569A (zh) 2021-09-01 2023-07-16 瑞士商諾華公司 包含ｔｅａｄ抑制劑的藥物組合及其用於癌症治療之用途
EP4389751A1 (en) 2021-09-03 2024-06-26 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
US20250145589A1 (en) 2021-09-22 2025-05-08 Sichuan Huiyu Pharmaceutical Co., Ltd. Pyridine derivative and use thereof
EP4408851A4 (en) * 2021-09-27 2025-09-17 Jacobio Pharmaceuticals Co Ltd POLYCYCLIC FUSED RING DERIVATIVES AND THEIR USE
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023103906A1 (zh) * 2021-12-07 2023-06-15 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
US20250282782A1 (en) 2021-12-17 2025-09-11 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4486345A1 (en) 2022-03-04 2025-01-08 Eli Lilly and Company Method of treatment including kras g12c inhibitors and shp2 inhibitors
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
CA3244383A1 (en) 2022-03-11 2023-09-14 Kumquat Biosciences Inc. HETEROCYCLIC COMPOUNDS AND RELATED USES
CA3247183A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company TREATMENT METHOD INCLUDING KRAS G12C INHIBITORS AND AURORA A INHIBITORS
WO2023199180A1 (en) 2022-04-11 2023-10-19 Novartis Ag Therapeutic uses of a krasg12c inhibitor
JP7735594B2 (ja) * 2022-05-19 2025-09-08 ジェネンテック， インコーポレイテッド アザ四環式オキサゼピン化合物及びその使用
EP4536364A1 (en) 2022-06-10 2025-04-16 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2023247360A1 (en) 2022-06-21 2023-12-28 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic compounds
WO2024009191A1 (en) * 2022-07-05 2024-01-11 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
JP2025525946A (ja) 2022-08-05 2025-08-07 カムクワット バイオサイエンシーズ インコーポレイテッド 複素環式化合物およびその使用
JP2025528126A (ja) * 2022-08-11 2025-08-26 ベイジン スウィッツアランド ゲゼルシャフト ミット ベシュレンクテル ハフツング 複素環式化合物、その組成物、及びそれらによる処置方法
WO2024041621A1 (en) * 2022-08-25 2024-02-29 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors
GB202212641D0 (en) 2022-08-31 2022-10-12 Jazz Pharmaceuticals Ireland Ltd Novel compounds
AR130796A1 (es) * 2022-10-18 2025-01-22 Ildong Pharmaceutical Co Ltd Compuestos triheterocíclicos novedosos
WO2024102421A2 (en) 2022-11-09 2024-05-16 Revolution Medicines, Inc. Compounds, complexes, and methods for their preparation and of their use
CN115583937B (zh) * 2022-11-21 2023-05-02 北京志道生物科技有限公司 以吲哚或氮杂吲哚为母核的kras抑制剂及其制备方法
WO2024110554A1 (en) 2022-11-23 2024-05-30 Syngenta Crop Protection Ag N-[(1 -[2-[6-(pyridazin-3-yl]-1,2,4-triazol-3-yl]ethyl]-quinazolin-4-amine and n-[1-[3-(6-(pyridazin-3-yl)pyrazin-2-yl]ethyl]-8-quinazolin-4-amine derivatives as pesticides
JP2025540269A (ja) * 2022-12-07 2025-12-11 ジャコバイオ ファーマスーティカルズ カンパニー リミテッド 縮合環化合物およびその使用
WO2024149214A1 (en) * 2023-01-10 2024-07-18 Nikang Therapeutics, Inc. Bifunctional compounds for degrading kras-12d via ubiquitin proteasome pathway
CN120548318A (zh) * 2023-01-18 2025-08-26 苏州赞荣医药科技有限公司 Kras g12d抑制剂和其用途
TW202504611A (zh) 2023-03-30 2025-02-01 美商銳新醫藥公司 用於誘導ｒａｓ ｇｔｐ水解之組合物及其用途
AU2024243852A1 (en) 2023-04-07 2025-11-06 Revolution Medicines, Inc. Macrocyclic ras inhibitors
AR132338A1 (es) 2023-04-07 2025-06-18 Revolution Medicines Inc Inhibidores de ras
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
TW202448897A (zh) 2023-04-14 2024-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2024243186A2 (en) * 2023-05-22 2024-11-28 Board Of Regents, The University Of Texas System Heterocyclic compounds as nras inhibitors
AU2024276994A1 (en) 2023-05-24 2025-10-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
TW202502779A (zh) 2023-06-30 2025-01-16 美商金橘生物科技公司 取代的雜芳族胺及其用途
WO2025022007A1 (en) 2023-07-27 2025-01-30 Syngenta Crop Protection Ag Pesticidally active quinazoline compounds
WO2025022008A1 (en) 2023-07-27 2025-01-30 Syngenta Crop Protection Ag Pesticidally active quinazoline compounds
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
TW202535891A (zh) * 2023-10-20 2025-09-16 美商默沙東有限責任公司 Ｋｒａｓ蛋白之小分子抑制劑
WO2025132349A1 (en) 2023-12-19 2025-06-26 Syngenta Crop Protection Ag Pesticidally active quinazoline compounds
WO2025132754A1 (en) 2023-12-21 2025-06-26 Syngenta Crop Protection Ag Pesticidally active quinazoline compounds
WO2025171055A1 (en) 2024-02-06 2025-08-14 Kumquat Biosciences Inc. Heterocyclic conjugates and uses thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025230971A1 (en) 2024-04-30 2025-11-06 Kumquat Biosciences Inc. Macrocyclic heterocycles as anticancer agents
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110251173A1 (en) * 2010-04-01 2011-10-13 Astrazeneca Ab Chemical compounds
CN105209460A (zh) * 2013-03-14 2015-12-30 诺华股份有限公司 作为突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2546727C (en) * 2003-11-20 2012-10-02 Children's Hospital Medical Center Gtpase inhibitors and methods of use
US9862701B2 (en) * 2014-09-25 2018-01-09 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356354A1 (en) * 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110251173A1 (en) * 2010-04-01 2011-10-13 Astrazeneca Ab Chemical compounds
CN105209460A (zh) * 2013-03-14 2015-12-30 诺华股份有限公司 作为突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112390818A (zh) * 2019-08-12 2021-02-23 劲方医药科技(上海)有限公司 取代的杂芳环并二氢嘧啶酮衍生物，其制法与医药上的用途
TWI799871B (zh) * 2020-05-27 2023-04-21 大陸商勁方醫藥科技(上海)有限公司 三環并環類化合物，其製法與醫藥上的用途
CN115551867B (zh) * 2020-05-27 2024-02-20 劲方医药科技(上海)有限公司 稠合三环类化合物、其药物组合物及用途
WO2021239058A1 (zh) * 2020-05-27 2021-12-02 劲方医药科技(上海)有限公司 稠合三环类化合物、其药物组合物及用途
CN115551867A (zh) * 2020-05-27 2022-12-30 劲方医药科技(上海)有限公司 稠合三环类化合物、其药物组合物及用途
CN114075219B (zh) * 2020-08-14 2023-11-14 江苏恒瑞医药股份有限公司 喹啉稠环类衍生物、其制备方法及其在医药上的应用
CN114075219A (zh) * 2020-08-14 2022-02-22 江苏恒瑞医药股份有限公司 喹啉稠环类衍生物、其制备方法及其在医药上的应用
WO2022135610A1 (zh) * 2020-12-25 2022-06-30 武汉誉祥医药科技有限公司 四并环化合物及其药物组合物和应用
CN114685531A (zh) * 2020-12-25 2022-07-01 武汉誉祥医药科技有限公司 四并环化合物及其药物组合物和应用
CN116867792A (zh) * 2021-02-09 2023-10-10 基因泰克公司 四环氧氮杂䓬化合物及其用途
WO2022188729A1 (en) * 2021-03-07 2022-09-15 Jacobio Pharmaceuticals Co., Ltd. Fused ring derivatives useful as kras g12d inhibitors
WO2022194245A1 (zh) * 2021-03-17 2022-09-22 劲方医药科技(上海)有限公司 嘧啶并环类化合物及其制法和用途
WO2022199587A1 (zh) * 2021-03-24 2022-09-29 南京明德新药研发有限公司 嘧啶并杂环类化合物及其应用
CN117083281A (zh) * 2021-03-24 2023-11-17 南京明德新药研发有限公司 嘧啶并杂环类化合物及其应用
CN116113632B (zh) * 2021-03-30 2025-08-29 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
CN116113632A (zh) * 2021-03-30 2023-05-12 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
WO2022206723A1 (zh) * 2021-03-30 2022-10-06 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
WO2022268051A1 (zh) * 2021-06-21 2022-12-29 江苏恒瑞医药股份有限公司 稠合四环类化合物、其制备方法及其在医药上的应用
WO2023274383A1 (zh) * 2021-07-02 2023-01-05 上海迪诺医药科技有限公司 Kras g12d抑制剂及其应用
EP4365176A4 (en) * 2021-07-02 2025-06-25 Shanghai de Novo Pharmatech Co., Ltd. KRAS G12D INHIBITOR AND ITS USE
WO2023001123A1 (zh) * 2021-07-19 2023-01-26 上海艾力斯医药科技股份有限公司 新型吡啶并嘧啶衍生物
WO2023001141A1 (en) * 2021-07-23 2023-01-26 Shanghai Zion Pharma Co. Limited Kras g12d inhibitors and uses thereof
WO2023030385A1 (zh) * 2021-08-31 2023-03-09 劲方医药科技(上海)有限公司 嘧啶并环类化合物及其制法和用途
WO2023066371A1 (zh) * 2021-10-22 2023-04-27 江苏恒瑞医药股份有限公司 含氮的四环化合物、其制备方法及其在医药上的应用
WO2023072297A1 (zh) * 2021-11-01 2023-05-04 江苏恒瑞医药股份有限公司 含氮的四环化合物、其制备方法及其在医药上的应用
WO2024022507A1 (zh) * 2022-07-29 2024-02-01 江苏恒瑞医药股份有限公司 一种包含kras g12d抑制剂的药物组合物
WO2024032704A1 (en) * 2022-08-11 2024-02-15 Beigene, Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2024032702A1 (en) * 2022-08-11 2024-02-15 Beigene, Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2024051721A1 (en) * 2022-09-07 2024-03-14 Nikang Therapeutics, Inc. Tetracyclic derivatives as kras inhibitors
WO2024120419A1 (en) * 2022-12-06 2024-06-13 Zai Lab (Shanghai) Co., Ltd. Fused tetracyclic compounds as kras g12d modulators and uses thereof
WO2024138486A1 (en) * 2022-12-29 2024-07-04 Nikang Therapeutics, Inc. Tetracyclic derivatives as kras inhibitors
WO2024197503A1 (en) * 2023-03-27 2024-10-03 Nikang Therapeutics , Inc. Tricyclic derivatives as kras inhibitors
WO2024217545A1 (zh) * 2023-04-21 2024-10-24 江苏恒瑞医药股份有限公司 一种含氮四环化合物的结晶形式及其制备方法
WO2024230734A1 (en) * 2023-05-08 2024-11-14 Jacobio Pharmaceuticals Co., Ltd. K-ras inhibitors and use thereof

Also Published As

Publication number Publication date
TW201906848A (zh) 2019-02-16
WO2018206539A1 (en) 2018-11-15
US20220127281A1 (en) 2022-04-28
AR111776A1 (es) 2019-08-21
JP2020519589A (ja) 2020-07-02
EP3621968A1 (en) 2020-03-18
US20200109153A1 (en) 2020-04-09
CA3061650A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
CN110603258A (zh) 抑制g12c突变型ras蛋白的杂芳基化合物
JP7453989B2 (ja) 抗癌剤として有用な縮合三環式化合物
JP7138724B2 (ja) 四環式ヘテロアリール化合物
CN117241801A (zh) 抑制泛素特异性蛋白酶1（usp1）
CN105683188B (zh) 作为fgfr4抑制剂的稠环二环吡啶基衍生物
CN101365701B (zh) 吡咯并三嗪激酶抑制剂
CN104884458B (zh) 作为蛋白质激酶抑制剂的稠合杂环化合物
CN104837829B (zh) 抑制剂化合物
CN112334451A (zh) 作为激酶抑制剂的杂环化合物
JP2012507512A (ja) アミロイドβのモジュレーター
WO2005118588A1 (ja) 縮合複素環化合物
CN110062758A (zh) 作为rho-激酶抑制剂的二环二氢嘧啶-甲酰胺衍生物
CN116057045A (zh) 成纤维细胞生长因子受体激酶抑制剂
CN104837844B (zh) 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
CN114401955A (zh) 细胞周期蛋白依赖性激酶的抑制剂
KR20060129040A (ko) 세포 증식 억제제로서의이미다졸로-5-일-2-아닐리노피리미딘
CN114340634A (zh) 作为激酶抑制剂的杂环化合物
CN116096707A (zh) 成纤维细胞生长因子受体激酶的抑制剂
CN111936144A (zh) Jak抑制剂
JP2007517007A (ja) Ｔｉｅ２（ＴＥＫ）活性を持つピリミジン
CN115873000A (zh) 异喹啉酮类及喹唑啉酮类化合物及其组合物和用途
CN113227100B (zh) 噻吩并吡啶酮化合物
CN115485273A (zh) 作为sstr4激动剂的n-(杂环基和杂环基烷基)-3-苯甲基吡啶-2-胺衍生物
CN111763217B (zh) 一类噻吩并氮杂环类化合物、制备方法和用途
CN115611888A (zh) 吡啶并嘧啶酮类衍生物及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191220

WD01 Invention patent application deemed withdrawn after publication